Delivery of viral vectors for gene therapy in intimal hyperplasia and restenosis in atherosclerotic swine

Sannette Hall, Devendra K. Agrawal

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

Cardiovascular diseases including atherosclerosis are a major financial and health burden globally. Inflammation associated with atherosclerosis results in the development of plaques that can rupture causing thrombosis, stroke, or death. The most widely used treatment for the removal of atherosclerotic plaques is percutaneous transluminal coronary angioplasty (PTCA) with or without stenting. Although this is a safer and minimally invasive method, restenosis and intimal hyperplasia after interventional procedure remains a major hurdle and more refined approaches are needed. Studies in large animal models such as pigs have facilitated a greater understanding of the underlying mechanisms of the disease and provided novel targets for therapeutic intervention. In pre-clinical studies, viral vector gene therapy has emerged as a promising option for the reduction and/or prevention of restenosis and intimal hyperplasia. Although studies in animal models have generated promising results, clinical trials have yet to prove the clinical efficacy of gene therapy in coronary artery diseases. In this review, we examined and critically reviewed the most recent advances in viral vector gene therapy obtained from studies using porcine model of atherosclerosis.

Original languageEnglish (US)
Pages (from-to)918-927
Number of pages10
JournalDrug Delivery and Translational Research
Volume8
Issue number4
DOIs
StatePublished - Aug 1 2018

Fingerprint

Tunica Intima
Viral Genes
Genetic Therapy
Hyperplasia
Atherosclerosis
Swine
Animal Models
Coronary Balloon Angioplasty
Atherosclerotic Plaques
Coronary Artery Disease
Rupture
Thrombosis
Cardiovascular Diseases
Stroke
Clinical Trials
Inflammation
Health
Therapeutics

All Science Journal Classification (ASJC) codes

  • Pharmaceutical Science

Cite this

Delivery of viral vectors for gene therapy in intimal hyperplasia and restenosis in atherosclerotic swine. / Hall, Sannette; Agrawal, Devendra K.

In: Drug Delivery and Translational Research, Vol. 8, No. 4, 01.08.2018, p. 918-927.

Research output: Contribution to journalReview article

@article{a5d9b1aeb85444e2b8162e370ad19e32,
title = "Delivery of viral vectors for gene therapy in intimal hyperplasia and restenosis in atherosclerotic swine",
abstract = "Cardiovascular diseases including atherosclerosis are a major financial and health burden globally. Inflammation associated with atherosclerosis results in the development of plaques that can rupture causing thrombosis, stroke, or death. The most widely used treatment for the removal of atherosclerotic plaques is percutaneous transluminal coronary angioplasty (PTCA) with or without stenting. Although this is a safer and minimally invasive method, restenosis and intimal hyperplasia after interventional procedure remains a major hurdle and more refined approaches are needed. Studies in large animal models such as pigs have facilitated a greater understanding of the underlying mechanisms of the disease and provided novel targets for therapeutic intervention. In pre-clinical studies, viral vector gene therapy has emerged as a promising option for the reduction and/or prevention of restenosis and intimal hyperplasia. Although studies in animal models have generated promising results, clinical trials have yet to prove the clinical efficacy of gene therapy in coronary artery diseases. In this review, we examined and critically reviewed the most recent advances in viral vector gene therapy obtained from studies using porcine model of atherosclerosis.",
author = "Sannette Hall and Agrawal, {Devendra K.}",
year = "2018",
month = "8",
day = "1",
doi = "10.1007/s13346-017-0409-0",
language = "English (US)",
volume = "8",
pages = "918--927",
journal = "Drug Delivery and Translational Research",
issn = "2190-393X",
publisher = "Springer Publishing Company",
number = "4",

}

TY - JOUR

T1 - Delivery of viral vectors for gene therapy in intimal hyperplasia and restenosis in atherosclerotic swine

AU - Hall, Sannette

AU - Agrawal, Devendra K.

PY - 2018/8/1

Y1 - 2018/8/1

N2 - Cardiovascular diseases including atherosclerosis are a major financial and health burden globally. Inflammation associated with atherosclerosis results in the development of plaques that can rupture causing thrombosis, stroke, or death. The most widely used treatment for the removal of atherosclerotic plaques is percutaneous transluminal coronary angioplasty (PTCA) with or without stenting. Although this is a safer and minimally invasive method, restenosis and intimal hyperplasia after interventional procedure remains a major hurdle and more refined approaches are needed. Studies in large animal models such as pigs have facilitated a greater understanding of the underlying mechanisms of the disease and provided novel targets for therapeutic intervention. In pre-clinical studies, viral vector gene therapy has emerged as a promising option for the reduction and/or prevention of restenosis and intimal hyperplasia. Although studies in animal models have generated promising results, clinical trials have yet to prove the clinical efficacy of gene therapy in coronary artery diseases. In this review, we examined and critically reviewed the most recent advances in viral vector gene therapy obtained from studies using porcine model of atherosclerosis.

AB - Cardiovascular diseases including atherosclerosis are a major financial and health burden globally. Inflammation associated with atherosclerosis results in the development of plaques that can rupture causing thrombosis, stroke, or death. The most widely used treatment for the removal of atherosclerotic plaques is percutaneous transluminal coronary angioplasty (PTCA) with or without stenting. Although this is a safer and minimally invasive method, restenosis and intimal hyperplasia after interventional procedure remains a major hurdle and more refined approaches are needed. Studies in large animal models such as pigs have facilitated a greater understanding of the underlying mechanisms of the disease and provided novel targets for therapeutic intervention. In pre-clinical studies, viral vector gene therapy has emerged as a promising option for the reduction and/or prevention of restenosis and intimal hyperplasia. Although studies in animal models have generated promising results, clinical trials have yet to prove the clinical efficacy of gene therapy in coronary artery diseases. In this review, we examined and critically reviewed the most recent advances in viral vector gene therapy obtained from studies using porcine model of atherosclerosis.

UR - http://www.scopus.com/inward/record.url?scp=85049201454&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85049201454&partnerID=8YFLogxK

U2 - 10.1007/s13346-017-0409-0

DO - 10.1007/s13346-017-0409-0

M3 - Review article

VL - 8

SP - 918

EP - 927

JO - Drug Delivery and Translational Research

JF - Drug Delivery and Translational Research

SN - 2190-393X

IS - 4

ER -